Holen Sie sich die Stockscreener-App
118.23
0.19%
0.22
Handel nachbörslich:
118.23
Schlusskurs vom Vortag:
$118.01
Offen:
$118.51
24-Stunden-Volumen:
548.44K
Relative Volume:
0.60
Marktkapitalisierung:
$7.15B
Einnahmen:
$3.99B
Nettoeinkommen (Verlust:
$463.16M
KGV:
16.65
EPS:
7.1
Netto-Cashflow:
$1.10B
1W Leistung:
+4.75%
1M Leistung:
+10.37%
6M Leistung:
-3.12%
1J Leistung:
+7.93%
1-Tages-Spanne:
$116.65
$118.72
1-Wochen-Bereich:
$111.20
$119.48
52-Wochen-Spanne:
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Firmenname
Jazz Pharmaceuticals Plc
Sektor
Branche
Telefon
353-1-634-7800
Adresse
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Vergleichen Sie JAZZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
118.23 | 7.14B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-15 | Eingeleitet | Deutsche Bank | Buy |
| 2025-03-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-26 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Eingeleitet | Goldman | Buy |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-06-12 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-12-09 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Buy |
| 2022-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-11-19 | Fortgesetzt | Goldman | Buy |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-10-05 | Eingeleitet | Citigroup | Buy |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-05-19 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-14 | Herabstufung | Goldman | Neutral → Sell |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Eingeleitet | Jefferies | Buy |
| 2020-03-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Neutral |
| 2019-08-21 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2018-11-08 | Bestätigt | B. Riley FBR | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Bestätigt | H.C. Wainwright | Neutral |
| 2018-03-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
Is Jazz Pharmaceuticals plc a good long term investmentOverwhelming financial success - PrintWeekIndia
What analysts say about Jazz Pharmaceuticals plc stockSuperior portfolio returns - PrintWeekIndia
Idiopathic Hypersomnia Treatment Market Propelled by Rising - openPR.com
Will Jazz Pharmaceuticals plc stock benefit from AI tech trendsExplosive capital gains - jammulinksnews.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Jazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference - MSN
What drives Jazz Pharmaceuticals plc stock priceUnmatched market performance - Autocar Professional
Jazz Pharmaceuticals plc Stock Analysis and ForecastRecord-setting profit potential - jammulinksnews.com
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025 - 富途牛牛
Lacklustre Performance Is Driving Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Low P/E - simplywall.st
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - GlobeNewswire Inc.
Jazz Pharmaceuticals Stock Offers Buying Opportunity After Slump, Deutsche Bank Says - MarketScreener
Jazz Pharmaceuticals (JAZZ) Receives Buy Rating from Deutsche Ba - GuruFocus
Deutsche Bank initiates Jazz Pharmaceuticals stock with Buy rating By Investing.com - Investing.com Nigeria
Deutsche Bank Initiates Jazz Pharmaceuticals at Buy With $152 Price Target - MarketScreener
What makes Jazz Pharmaceuticals plc stock price move sharplyFree Capital Allocation Plans - beatles.ru
Ireland: Renee Gala elected CEO at Jazz Pharma - Investors in Healthcare
Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update - BioPharma Dive
Jazz Pharmaceuticals Appoints Renee Gala as New CEO - The Globe and Mail
Jazz Pharmaceuticals names Renee Gala as next CEO By Investing.com - Investing.com South Africa
Innoviva, Inc. shares rise 2.05% premarket after Jazz Pharmaceuticals announces CEO succession plan. - AInvest
Jazz Pharmaceuticals names Renee Gala as next CEO - Investing.com Australia
1 Profitable Stock with Solid Fundamentals and 2 to Brush Off - Yahoo Finance
Finanzdaten der Jazz Pharmaceuticals Plc-Aktie (JAZZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):